Zhang F, Zhang H, Liu YM, Tang FS. Helicobacter pylori, esophageal precancerous lesions, and proton pump inhibitor overuse. World J Gastroenterol 2024; 30(42): 4591-4596 [PMID: 39563751 DOI: 10.3748/wjg.v30.i42.4591]
Corresponding Author of This Article
Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Research Domain of This Article
Substance Abuse
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 14, 2024; 30(42): 4591-4596 Published online Nov 14, 2024. doi: 10.3748/wjg.v30.i42.4591
Helicobacter pylori, esophageal precancerous lesions, and proton pump inhibitor overuse
Feng Zhang, Hang Zhang, Yan-Miao Liu, Fu-Shan Tang
Feng Zhang, Hang Zhang, Fu-Shan Tang, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Feng Zhang, Hang Zhang, Fu-Shan Tang, Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Yan-Miao Liu, The First Clinical Institute, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Fu-Shan Tang, Key Laboratory of Clinical Pharmacy in Zunyi City, Zunyi Medical University, Zunyi 563006, Guizhou Province, China
Author contributions: Zhang F drafted and revised the manuscript; Zhang H and Liu YM provided discussion and literature support; Tang FS contributed to idea generation, revised the manuscript, and provided supervision; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com
Received: August 21, 2024 Revised: September 20, 2024 Accepted: October 8, 2024 Published online: November 14, 2024 Processing time: 71 Days and 4.3 Hours
Abstract
This article reviews the cohort study published in the World Journal of Gastroenterology, which reported low rates of Helicobacter pylori (H. pylori) infection among esophageal cancer (EC) patients, coupled with proton pump inhibitor (PPI) overuse. These findings suggest a potential protective role of H. pylori against EC and indicate a possible association between PPI use and increased cancer risk. In light of these findings, our article examines the complex relationship between H. pylori and esophageal precancerous lesions, exploring the potential underlying mechanisms. We also address growing concerns regarding PPI overuse, including its potential effects on cancer therapy efficacy and the risk of drug interactions. Ultimately, this article highlights the urgent need for further research to evaluate the safety and efficacy of PPIs in cancer patients and to better understand their broader implications.
Core Tip: This article reviews a recent cohort study suggesting that Helicobacter pylori (H. pylori) infection may protect against esophageal cancer. We discuss the controversial link between H. pylori and esophageal precancerous lesions and address risks associated with proton pump inhibitor (PPI) overuse. The implications for cancer treatment and the need for further research on PPI safety and efficacy in cancer patients are highlighted.
